

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)



(10) International Publication Number
WO 2022/094275 A1

(51) International Patent Classification:

A61K 31/573 (2006.01) *A61P 37/00* (2006.01)
A61K 38/20 (2006.01) *C07K 14/55* (2006.01)
A61P 17/06 (2006.01)

(21) International Application Number:

PCT/US2021/057352

(22) International Filing Date:

29 October 2021 (29.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/198,615 29 October 2020 (29.10.2020) US
63/123,991 10 December 2020 (10.12.2020) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **WANG, Alice L.**; c/o Bristol-myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US). **STRUTHERS, Mary**; c/o
Bristol-myers Squibb Company, Route 206 and Province
Line Road, Princeton, New Jersey 08543 (US). **MAC-
GORMAN, Kimberly**; c/o Bristol-myers Squibb Compa-
ny, Route 206 and Province Line Road, NJ, Princeton 08543
(US). **RAY, Neelanjana**; c/o Bristol-myers Squibb Com-
pany, Route 206 and Province Line Road, Princeton, New
Jersey 08543 (US). **PRICE, Karen D.**; c/o Bristol-my-
ers Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **SHARDA, Nidhi**; c/
o Bristol-myers Squibb Company, Route 206 and Province
Line Road, Princeton, New Jersey 08543 (US). **HUR, Eun
Mi**; c/o Bristol-myers Squibb Company, Route 206 and
Province Line Road, Princeton, New Jersey 08543 (US).
MADIA, Priyanka Apurva; c/o Bristol-myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein &
Fox P.L.L.C., 1100 New York Avenue, NW, Washington,
District of Columbia 20005 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/094275 A1

(54) Title: FUSION PROTEINS FOR THE TREATMENT OF DISEASE

(57) Abstract: Disclosed herein are methods of treating a disease or disorder in a subject in need thereof, comprising administering to the subject one or more doses of an Interleukin-2 (IL2) fusion protein, wherein the dose is from about 0.1 mg to about 9 mg. Also disclosed herein are methods of treating a disease or disorder in a subject in need thereof, comprising administering to the subject an dose of an IL2 fusion protein, wherein the dose is greater than about 9 mg. The IL2 fusion proteins used in the methods disclosed herein comprise: (a) a first polypeptide comprising an IL2 polypeptide; and (b) a second polypeptide comprising an extracellular domain of an IL2 Receptor alpha (IL2R) polypeptide. In some aspects, the disease or disorder is an immune-mediated disease, such as systemic lupus erythematosus. In some aspects, the methods further administering a corticosteroid to the subject.